Evaluation of Diagnostic Criteria for Creutzfeldt Jakob Disease

• Sponsor: Peking University Third Hospital (Other)
• Overall Status: Completed
• CT.gov ID: NCT04944732
• Collaborator: Centers for Disease Control and Prevention, China (Other)
• Enrollment: 30
• Actual Duration (Months): 240

Study Details

Study Description

Brief Summary

Clinicians know little about Creutzfeldt Jakob disease, and they are not proficient in the diagnostic criteria of Creutzfeldt Jakob disease, so it is easy to misdiagnose or delay the diagnosis. As a rare central nervous system disease, it is necessary, feasible and practical to evaluate the diagnostic criteria of Creutzfeldt Jakob disease.

Condition or Disease	Intervention/Treatment	Phase
Creutzfeldt Jakob Disease	Diagnostic Test: laboratory examination, auxiliary examination, pathological results

Detailed Description

To master the clinical application of the diagnosis of Creutzfeldt Jakob disease (WS / T 562-2017) and the problems in the implementation process; The rationality, practicability and operability of the diagnostic criteria were evaluated scientifically; Reduce the misdiagnosis rate; To provide clinical basis and suggestions for further improving the diagnostic criteria. Through consulting the literature of Creutzfeldt Jakob disease, the clinical manifestations, laboratory examination, auxiliary examination and pathological results of Creutzfeldt Jakob disease were analyzed and compared with the current diagnostic criteria; The clinical diagnosis and misdiagnosis of Creutzfeldt Jakob disease were analyzed; To train medical staff at all levels to apply the diagnostic criteria of Creutzfeldt Jakob disease, and to discuss the clinical cases of Creutzfeldt Jakob disease in many hospitals.

Study Design

• Study Type: Observational
• Actual Enrollment: 30 participants
• Observational Model: Case-Only
• Time Perspective: Retrospective
• Official Title: Follow up Evaluation of Diagnostic Criteria for Creutzfeldt Jakob Disease (WS / T 562-2017)
• Actual Study Start Date: Jan 1, 2000
• Actual Primary Completion Date: Jan 1, 2020
• Actual Study Completion Date: Jan 1, 2020

Arms and Interventions

Arm	Intervention/Treatment
Patients with Creutzfeldt Jakob disease Patients with Creutzfeldt Jakob disease	Diagnostic Test: laboratory examination, auxiliary examination, pathological results; Personal information (sex, age), medical history of present disease, past medical history, family history, symptoms and signs, supplementary examination items (including laboratory examination, impact examination)

Outcome Measures

Primary Outcome Measures

1. Clinical manifestations [1 year]

   Clinical manifestations of patients

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Patients with Creutzfeldt Jakob disease

Exclusion Criteria:

• none

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Peking University Third Hospital
• Centers for Disease Control and Prevention, China

Investigators

• Principal Investigator: Li Xiaogang, Peking University Third Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Peking University Third Hospital
• ClinicalTrials.gov Identifier: NCT04944732
• Other Study ID Numbers: M2020331
• First Posted: Jun 30, 2021
• Last Update Posted: Jun 30, 2021
• Last Verified: Jun 1, 2021

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Creutzfeldt-Jakob Syndrome

Study Results

No Results Posted as of Jun 30, 2021